Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 6/20 | 0.51 |
| ▸ | NR1H2 | P55055 | 6/20 | 0.51 |
| ▸ | NR1H3 | Q13133 | 6/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16455493 | 0.89 | RXRA (0.49) | RXRANR1H2NR1H3PTGS2PIK3CA | |
| SCHEMBL16455482 | 0.88 | HSP90AA1 (0.49) | RXRANR1H2NR1H3PTGS2PIK3CA | |
| SCHEMBL3472596 | 0.87 | RXRA (0.66) | RXRANR1H2NR1H3PTGS2PIK3CA | |
| SCHEMBL15229773 | 0.85 | NR1H2 (0.58) | RXRANR1H2NR1H3PTGS2 | |
| SCHEMBL16455494 | 0.85 | NR1H2 (0.46) | RXRANR1H2NR1H3PTGS2PIK3CA | |
| SCHEMBL16455257 | 0.85 | RXRA (0.46) | RXRANR1H2NR1H3PTGS2PIK3CA | |
| SCHEMBL16455400 | 0.85 | RXRA (0.46) | RXRANR1H2NR1H3PTGS2PIK3CA | |
| SCHEMBL16455495 | 0.84 | NR1H2 (0.44) | RXRANR1H2NR1H3PTGS2PIK3CA | |
| SCHEMBL16770160 | 0.83 | CARM1 (0.47) | RXRANR1H2NR1H3PTGS2HSP90AA1 | |
| SCHEMBL16455475 | 0.83 | NR1H2 (0.43) | RXRANR1H2NR1H3PTGS2PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210101895-A1 | LIVER X RECEPTOR (LXR) MODULATORS FOR THE TREATMENT OF DERMAL DISEASES, DISORDERS AND CONDITIONS | RALEXAR THERAPEUTICS, INC. | 2021-04-08 | — | — | US | disclosed |
| EP-3441390-A1 | LIVER X RECEPTOR (LXR) MODULATORS FOR THE TREATMENT OF DERMAL DISEASES, DISORDERS AND CONDITIONS | Ralexar Therapeutics, Inc. (US) | 2019-02-13 | — | — | EP | disclosed |
| US-20170334897-A1 | Liver X Receptor (LXR) Modulators For The Treatment Of Dermal Diseases, Disorders And Conditions | ALEXAR THERAPEUTICS, INC. | 2017-11-23 | — | — | US | disclosed |
| US-9637481-B2 | Liver X receptor (LXR) modulators for the treatment of dermal diseases, disorders and conditions | RALEXAR THERAPEUTICS, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-20150152094-A1 | LIVER X RECEPTOR (LXR) MODULATORS FOR THE TREATMENT OF DERMAL DISEASES, DISORDERS AND CONDITIONS | RALEXAR THERAPEUTICS, INC. | 2015-06-04 | — | — | US | disclosed |
| US-8987318-B2 | Liver X receptor (LXR) modulators for the treatment of dermal diseases, disorders and conditions | ALEXAR THERAPEUTICS, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20150045399-A1 | Liver X Receptor (LXR) Modulators For The Treatment Of Dermal Diseases, Disorders And Conditions | ALEXAR THERAPEUTICS, INC. (US) | 2015-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045399-A1 | Liver X Receptor (LXR) Modulators For The Treatment Of Dermal Diseases, Disorders And Conditions | NR1H2, NR1H3, RXRA | RXRA 3/4885NR1H2 1/4885NR1H3 2/4885 |
| US-20170334897-A1 | Liver X Receptor (LXR) Modulators For The Treatment Of Dermal Diseases, Disorders And Conditions | NR1H2, NR1H3, RXRA | RXRA 3/4885NR1H2 1/4885NR1H3 2/4885 |
| US-20210101895-A1 | LIVER X RECEPTOR (LXR) MODULATORS FOR THE TREATMENT OF DERMAL DISEASES, DISORDERS AND CONDITIONS | NR1H2, NR1H3, RXRG | RXRA 4/4885NR1H2 1/4885NR1H3 2/4885 |
| US-20150152094-A1 | LIVER X RECEPTOR (LXR) MODULATORS FOR THE TREATMENT OF DERMAL DISEASES, DISORDERS AND CONDITIONS | NR1H2, NR1H3, RXRA | RXRA 3/4885NR1H2 1/4885NR1H3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.